Septerna (SEPN) has just been added to several Russell growth indices, including the Russell 3000 Growth and Russell 2000 Growth. This change often brings fresh attention from index-tracking funds.

The latest index additions come on top of a strong run in Septerna’s share price, with a 1 day share price return of 8.11% and a 30 day share price return of 23.64%. The year to date share price return of 33.45% and 1 year total shareholder return of 255.28% point to powerful momentum already in place.

If this kind of fast building interest in growth stories has your attention, it could be a good moment to scan a wider field of emerging opportunities through the 39 healthcare AI stocks

With Septerna now trading at $37.34 against an average analyst price target of $45.78, the key question is whether the current premium growth story still leaves upside on the table or whether the market is already pricing in future progress.

Preferred Price-to-Sales Multiple of 23.3x: Is it justified?

Septerna now trades at $37.34 with a strong recent share price run, but on a P/S ratio of 23.3x it screens as expensive against several benchmarks.

The price to sales ratio compares the company’s market value with its revenue, which can be useful for early stage or loss making biotechs where earnings are not yet positive. For Septerna, this multiple is being applied to annual revenue of $72.26m alongside a reported net loss of $36.04m, so investors are paying a high revenue premium while the company is still unprofitable.

Against the US Pharmaceuticals industry average P/S of 5.8x and a peer average of 3.3x, Septerna’s 23.3x stands at a much higher level. It also sits well above an estimated fair P/S ratio of 4.2x that the market could potentially gravitate toward if sentiment or expectations change.

Result: Price-to-sales of 23.3x (OVERVALUED)

However, Septerna’s premium P/S and ongoing net loss of $36.04m leave little margin for disappointment if revenue trends, partnerships, or trial progress fall short.

Next Steps

If the strength of the recent Septerna share price run has you leaning bullish, it is worth checking the underlying risk profile before settling on a view. Acting while interest is high can help you frame your stance, so take a closer look at the 2 important warning signs

Looking for more investment ideas beyond Septerna?

If Septerna has sharpened your interest in growth stories, do not stop here. Use the Simply Wall Street Screener to spot other opportunities before the crowd moves in.

• Target potential value opportunities by scanning companies that show up in the 44 high quality undervalued stocks and see which ones match your return and risk preferences.
• Prioritise resilience first by focusing on companies in the 71 resilient stocks with low risk scores so you can keep your portfolio aligned with your risk comfort zone.
• Hunt for future standouts by running the screener containing 19 high quality undiscovered gems and see which lesser known stocks fit the qualities you already look for.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.